Parkwood LLC maintained its position in Horizon Pharma Inc. (NASDAQ:HZNP) during the second quarter, Holdings Channel reports. The firm owned 101,900 shares of the biopharmaceutical company’s stock at the end of the second quarter. Parkwood LLC’s holdings in Horizon Pharma were worth $1,678,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of HZNP. Canada Pension Plan Investment Board purchased a new position in Horizon Pharma during the first quarter worth approximately $114,000. Exane Derivatives purchased a new position in Horizon Pharma during the first quarter worth approximately $166,000. 1st Global Advisors Inc. purchased a new position in Horizon Pharma during the second quarter worth approximately $216,000. Carl Domino Inc increased its position in Horizon Pharma by 36.4% in the second quarter. Carl Domino Inc now owns 15,000 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 4,000 shares during the period. Finally, Virginia Retirement System purchased a new position in Horizon Pharma during the first quarter worth approximately $282,000. Institutional investors and hedge funds own 85.25% of the company’s stock.
Shares of Horizon Pharma Inc. (NASDAQ:HZNP) traded up 0.10% during trading on Friday, hitting $19.43. The stock had a trading volume of 2,149,666 shares. Horizon Pharma Inc. has a one year low of $12.86 and a one year high of $23.70. The stock’s market cap is $3.13 billion. The stock’s 50-day moving average price is $20.20 and its 200 day moving average price is $17.61.
Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. The firm earned $257.40 million during the quarter, compared to analyst estimates of $235.43 million. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business’s revenue was up 48.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.39 EPS. On average, equities analysts forecast that Horizon Pharma Inc. will post $2.15 EPS for the current year.
A number of equities analysts recently commented on HZNP shares. Vetr downgraded Horizon Pharma from a “strong-buy” rating to a “buy” rating and set a $18.42 price target for the company. in a research note on Monday, May 30th. Guggenheim reiterated a “buy” rating and issued a $30.00 price target on shares of Horizon Pharma in a research note on Monday, August 1st. Brean Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Horizon Pharma in a research note on Thursday, July 14th. Goldman Sachs Group Inc. started coverage on Horizon Pharma in a research note on Monday, June 6th. They issued a “buy” rating and a $24.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target on shares of Horizon Pharma in a research note on Wednesday, July 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Horizon Pharma presently has a consensus rating of “Buy” and a consensus target price of $30.00.
In other news, EVP Jeffrey W. Sherman sold 2,900 shares of the company’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.10% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma Inc. (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.